No abstract

Radical treatment in oligometastatic disease in NSCLC has Improved outcome in overall survival. We defined oligometastic disease in patients with less than five synchronous metastases and 3 organs and mediastinal lymph node involvement is not counted as a metastatic site. We describe a single center experience of an academic hospital of oncology assessed by computed tomography for diagnosis, and radiotherapy as a radical treatment. Materials and Methods: In this retrospective study we evaluate progression free survival using radiotherapy (stereotactic body radiotherapy and three-dimensional conformal radiotherapy) in patients with oligometastatic NSCLC with pathologically confirmed stage IV NSCLC with 5 synchronous metastases, and there were assessed by CT. All patients received four to six initial cycles of systemic treatment. We reviewed files from 2017 to 2019. During treatment of radiotherapy patients received pemetrexed as maintenance. Results: Sixteen patients were included in the analysis. The mean age was 62.5 years (range: 48-78 years). At diagnosis, 31% of patients presented with CNS metastases. Following radiotherapy, 16 (68.75%) patients achieved a stable disease, while 4 (25%) had a partial response and 1(6.25%) with complete response. The median PFS was 5.7 months (95% CI: 6.3-5.07). Conclusion: Patients with oligometastatic NSCLC who undergo radiotherapy have a favorable response and progression free survival.